9th International
Lung Cancer Network
23-25 June 2023 Athens Marriott Hotel, Athens Greece
Welcome
Dear Colleagues and Friends,
We are excited to invite you to join us at the 9th International Lung Cancer Network (ILCN) taking place on site at Athens, Greece from Friday 23rd to Sunday 25th June 2023.
This bi-annual international lung cancer meeting continues its tradition of multidisciplinary networking, by bringing together some of the top lung cancer experts, from across the globe. Debates, State-of-the Art lectures, multidisciplinary sessions, and extended panel discussions will encourage interaction with the faculty members and will address ongoing clinical challenges and controversies, in current lung cancer management. Participants will have the opportunity to understand the reasoning behind clinical trials, the interpretation of the results and the application in the clinical practice, for the optimal patient care. International lung cancer experts from the basic and clinical research, the academia and the industry will share their personal experiences and will present early clinical data, ongoing clinical trials, innovative technologies, and strategies, in the effort to provide state–of–the art care today and shape the future of lung cancer management.
We invite you to save the date for the 9th International Lung Cancer Network (ILCN) in Athens, Greece (23rd – 25th June 2023).
We hope you will join us on site for this very informative and timely meeting.
The chairs
Kostas Syrigos, MD, PhD, FCCP
Athens School of Medicine, GR
Roy S. Herbst, MD, PhD
Ensign Professor of Medicine
Deputy Director
Yale Cancer Center and Smilow Cancer Hospital
Assistant Dean for Translational Research
Yale School of Medicine
Fred Hirsch, MD, PhD
Icahn Medical School, Mount Sinai, NY
About The
Conference
The 9th International Lung Cancer Network (ILCN) will review the latest data on immunotherapy, targeted therapies, surgery, and radiation oncology, will present ongoing clinical trials, diagnostic technologies, and predictive strategies, in the effort to provide state–of–the art care today and shape the future of lung cancer management.
Athens Marriott Hotel, Syngrou Avenue 385, Athens, 17564 Greece
Learning Objectives
- Explain the optimal use of biomarkers in all stages of lung cancer.
- Discuss the emerging evidence of omics technologies and artificial intelligence in view of the application of precision medicine in thoracic malignancies.
- Debate the results from recent clinical trials and how these change the clinical practice.
- Apply patient characteristics, tumor markers, clinical trial evidence and combination treatment strategies to optimize the individualized approach
- Summarize of resistance to treatment and optimal sequencing of therapeutic strategies.
- Review the optimal therapeutic approaches in various subgroups of thoracic malignancies and in micrometastatic disease.
Target Audience
This appealing congress is addressed to medical, surgical, and radiation oncologists interested in the treatment of patients with lung cancer. Pathologists, Pulmonologists and basic scientists will also benefit from the multidisciplinary program. Fellows, nurses, family physician, pharmacists, researchers, and other health care professionals working in the area of thoracic malignancies are invited to participate.
Accreditation
CME/CE accreditation will be provided
Online Registration
Scientific Program
THE PERPETUAL QUEST OF NEW TARGETS
THE PERPETUAL QUEST OF NEW TARGETS
Chairs: George Lainakis, Vassilis Ramfidis, Lydia Abou - Asabeh
09:00-09:20 Transcending ALK resistance: Ilias Athanasiadis
09:20-09:40 Targeting HER2 in NSCLC: Anastasia Papafili
09:40-10:00 DLL3: an emerging target in SCLC: Fred Hirsch
10:00-10:20 Parp inhibitors combined with I-O: Marili Mani
10:20-10:30 Q&A
FROM THE BENCH TO BEDSIDE
FROM THE BENCH TO BEDSIDE
Chairs: Keith M. Kerr, Kalliopi Athanassiadi, Vasiliki Nikolaidou
10:30-10:50 Analyzing the tumor microenvironment in EGFR- positive disease: Jon Zugazagoitia
10:50-11:10 Targeting BRAF-mutant NSCLC: Maria Toki
11:10-11:30 Circulating Tumor DNA in the Treatment of Patients With LC: Natasha Leighl
Coffee Break – Delegates Networking
ΙNVITED LECTURE
ΙNVITED LECTURE
Chairs: Fred Hirsch, Christos Christodoulou
12:00-12:30 Dissecting the NSCLC tumor microenvironment: the good, the bad and the ugly: Kurt A. Schalper
ΙNVITED LECTURE
ΙNVITED LECTURE
Chairs: Ioannis G. Kaklamanos, Epaminondas Samantas
12:30-13:00 Lineage Plasticity in lung cancer: the Devil is in the Details: Triparna Sen
LUNG CANCER SUSCEPTIBILITY
LUNG CANCER SUSCEPTIBILITY
Chairs: Stelios Loukides, Eleftherios Zervas, Florentia Fostira
13:00-13:20 The hereditary element of LC:Periklis Makrythanasis
13:20-13:40 Long-term exposure to air pollution: Dionisios Spyratos
13:40-14:00 LC beyond smoking: Sofia Lampaki
INDUSTRY PIPELINE (I)
INDUSTRY PIPELINE (Ι)
Chairs: Alexios Strimpakos, Dimitra Kanaloupiti
14:00-14:30 Transform the Lung Cancer Therapeutic Landscape: Vincent E. Gaillard
Lunch Break – Delegates Networking
INDUSTRY PIPELINE (ΙΙ)
INDUSTRY PIPELINE (ΙΙ)
Chairs: Ioannis Gkiozos, Eleftheria Ntalakou
15:30-16:00 BMS: Designing the landscape of Lung Cancer: Constantin Makris
THE SMOKING STIGMA – SPONSORED SYMPOSIUM BY FAIRLIFE
THE SMOKING STIGMA – SPONSORED SYMPOSIUM BY FAIRLIFE
Chairs: Stamatina Demiri, Demosthenes Bouros
16:00-16:30 When the past haunts the management of a patient: Korina Pateli-Bell & Cynthia Mikkelsen
INVITED LECTURE
INVITED LECTURE
Chairs: Ioannis Boukovinas, Flora Zagouri
Understanding and overcoming therapeutic resistance in Small Cell Lung Cancer: Triparna Sen
NEUROENDOCRINE TUMORS OF THE LUNG
NEUROENDOCRINE TUMORS OF THE LUNG
Chairs: Haiying Cheng, Georgios Evangelou, Konstantinos - Marios Soultanis
17:00-17:30 Pathology & Molecular classification: Keith M. Kerr
17:30-18:00 Surgical considerations: Brendon Stiles
18:00-18:30 Molecular targets for therapy: Where do we go from here: Natasha Leighl
Coffee Break – Delegates Networking
State of the Art CLINICAL MANAGEMENT
Chairs: Filippos Koinis, Anastasios Boutis, Stefania Kokkali
19:00-19:30 SCLC: Salvage therapy: Haiying Cheng
19:30-20:00 Oncogenic fusions: Targeting ROS1, RET and NTRK: Fabrice Barlesi
20:00-20:30 NSCLC: Disease Progression after adjuvant IO: Natasha Leighl
OPENING CEREMONY
Chairs: Kostas Syrigos, Aristotelis Bamias
20:30-21:00 Precision Medicine in Oncology: Edward Chu
Cocktail Reception – Delegates Networking
LUNG CANCER IN THE ERA OF COVID19
LUNG CANCER IN THE ERA OF COVID19
Chairs: Evangelos Giamarellos-Bourboulis, Sotiris Moraitis, Petros Bakakos
09:00-09:20 LC screening challenges: Ioannis Gkiozos
09:20-09:40 Safety of LC surgery during the COVID19 pandemic: Levon Toufektzian
09:40-10:00 Optimizing LC management in the pandemic era: Iris Vlachantoni
10:00-10:20 Vaccination Guidelines for LC patients: Garyfallia Poulakou
10:20-10:30 Q&A
ΜESOTHELIOMA UPDATE
ΜESOTHELIOMA UPDATE
Chairs: Konstantinos Potaris, Kosmas Iliadis, Vasileios Skouras
10:30-10:50 WHO classification update of MPM: Ioannis Vamvakaris
10:50-11:10 Molecular targets for MPM: Future considerations: Marousa Kouvela
11:10-11:30 Radical surgery in MPM; is it possible?: Emmanuel Kefaloyannis
Coffee Break – Delegates Networking
DEVELOPMENTAL CANCER THERAPEUTICS
DEVELOPMENTAL CANCER THERAPEUTICS
Chairs: Marios Bakogeorgos, Sofia Baka, Konstantinos Samitas
12:30-12:50 The changing landscape of Clinical Trials: Lamprini Stournara
12:50-13:10 Real World Data & drug development: Eleni Kokkotou
13:10-13:30 Big Data & A.I. in drug development: Dimitrios Fotiadis
13:30-14:00 Detection of lung cancer using absent sequences in cfDNA and cfRNA: Ilias Georgakopoulos-Soares
Lunch Break – Delegates Networking
RADIOTHERAPY ISSUES IN THORACIC ONCOLOGY
RADIOTHERAPY ISSUES IN THORACIC ONCOLOGY
Chairs: Vasileios Kouloulias, Georgios Koukourakis, Zoi Kalaitzi
17:00-17:30 PCI: Time for reassessment? Suresh Senan
17:30-18:00 Combined use of Radiotherapy & TKIs: Ioannis Georgakopoulos
18:00-18:30 Combined use of Radiotherapy & Immunotherapy:George Maravelis
ΝAVIGATING THROUGH CONTRADICTORY RESULTS
ΝAVIGATING THROUGH CONTRADICTORY RESULTS
Chairs: Yesim Eralp, Helena Linardou, Vassilis Ramfidis
09:00-09:20 Aegean vs NADIM II: Giannis Mountzios
09:20-09:40 Impower010 vs. PEARLS: Mary O’ Brien
09:40-10:00 CheckMate 816 vs. IMpower 010: Antonio Passaro
10:00-10:20 Checkmate 816 vs PACIFIC: Mustafa Özguroglu
10:20-10.40 Keynote 189/407 vs Checkmate 9LA: Andriani Charpidou
10:40-11:00 Q&A
TREATING THE TISSUE
TREATING THE TISSUE
Chairs: Antonio Passaro, Nikolaos Touroutoglou, Sophia Tsagouli
11:00-11:15 NGS in clinical practice: do we really need it? How far are we?: Fred Hirsch
11:15-11:30 Applying liquid biopsy in the pathology service: Rajwanth Veluswamy
11:30-11:45 When we should/could rebiopsy: Keith M. Kerr
11:45-12:00 Maximizing the outcome from the pathology & molecular report: Jan von der Thusen
Coffee Break – Delegates Networking
ΙNVITED LECTURE
ΙNVITED LECTURE
Chairs: Solange Peters, Andriani Charpidou, Konstantinos Stefanidis
12:30-13:00 Oligometastasis in Lung Cancer: Where is the ceiling?: Heather Wakelee
DEBATE: NEOADJUVANT vs. ADJUVANT THERAPY IN OPERABLE NSCLC
DEBATE: NEOADJUVANT vs. ADJUVANT THERAPY IN OPERABLE NSCLC
Chairs: Charles Rudin, Kostas Syrigos
13:00-13:30 For the neoadjuvant treatment: Solange Peters
13:30-14:00 For the adjuvant treatment: Heather Wakelee
State of the Art – SPONSORED SYMPOSIUM by MSD
State of the Art – SPONSORED SYMPOSIUM by MSD
Chairs: Sofia Agelaki, Kostas Syrigos
14:00-14:30 Setting the survival standards in mNSCLC: Antonio Passaro
State of the Art Lecture – Sponsored by ASTRAZENECA
State of the Art Lecture – Sponsored by ASTRAZENECA
Chairs: Christos Panopoulos, Christos Kosmas
14:30 – 15:00 Right Patient, Right Treatment at the Right Time: Jon Zugazagoitia, Jan von der Thusen
Lunch Break – Delegates Networking
DESIGNING THE FUTURE – INDUSTRY PIPELINE (ΙΙΙ)
DESIGNING THE FUTURE – INDUSTRY PIPELINE (ΙΙΙ)
Chairs: Helen Gogas, Dimitris Dionysopoulos
Presenter: Zsofia Nagy-Erdei
PRACTICE CHANGING CONSIDERATIONS
PRACTICE CHANGING CONSIDERATIONS
Chairs: Pasi A. Jänne, Ilias Athanasiadis, Oraianthi Fiste
16:30-17:00 Immunotherapy in mNSCLC: when should we stop?: Heather Wakelee
17:00-17:30 How can we identify the minimal residual disease?: Charles Rudin
17:30-18:00 Can we convert unresectable NSCLC disease to resectable?: Witold Rzyman
Coffee Break – Delegates Networking
OPTIMAL USE OF TKIs
OPTIMAL USE OF TKIs
Chairs: Sarah Goldberg, Maria Theochari, Dimitrios Dionysopoulos
18:30-18:50 Peri-operative TKI in EGFR mutant tumors and beyond: Jon Zugazagoitia
18:50-19:10 Uncommon EGFR mutations: Rajwanth Veluswamy
19:10-19:30 How targetable is KRAS?: Kostas Syrigos
19:30-19:50 Targeting c-Met: Pasi A. Jänne
19:50-20:10 Whole Transcriptome Sequencing in therapeutic Decision making: Haiying Cheng
DESIGNING THE FUTURE OF LUNG CANCER TREATMENT
DESIGNING THE FUTURE OF LUNG CANCER TREATMENT
Chairs: Fred Hirsch, Athanasios Kotsakis, Ioannis Boukovinas
20:10-20:25 Latest advances in immunotherapy biomarkers for NSCLC: Kurt A. Schalper
20:25-20:40 SCLC: After Immunotherapy what?: Charles Rudin
20:40-20:55 Overcoming IO resistance: Sarah Goldberg
20:55-21:10 Overcoming EGFR resistance: Pasi A. Jänne
State of the Art CLINICAL MANAGEMENT
State of the Art CLINICAL MANAGEMENT
Chairs: George Sotiropoulos, Kalliopi Athanassiadi, Panagiotis Pandelakos
09:00-09:20 Segmectomy or Lobectomy? Brendon Stiles
09:20-09:40 Optimal Management of Brain Mets: Sarah Goldberg
09:40-10:00 Adrenal Solitary Lesion: Ernestos Beroukas
10:00-10:20 Systemic Treatment of oligometastatic disease: Yesim Eralp
10:20-10:30 Q&A
INEQUALITIES IN LUNG CANCER MANAGEMENT: THE ATHENS DECLARATION
INEQUALITIES IN LUNG CANCER MANAGEMENT: THE ATHENS DECLARATION
Chairs: Kostas Syrigos, Roy S. Herbst, Fred Hirsch
09:00-09:10 Ethnic & gender discriminations in Lung Cancer diagnosis & Management: Heather Wakelee
09:00-09:10 Gender discrepancies: Sofia Agelaki
09:20-09:30 The North America picture: Roy S. Herbst
09:30-09:40 The Developing countries picture: Ola Khorshid
09:40-09:50 Mind the Gap: Kostas Syrigos / Mary E. Bussell
09:50-10:30 Open Discussion by all participants
PERSONALIZED MEDICINE: SO CLOSE AND YET SO FAR
PERSONALIZED MEDICINE: SO CLOSE AND YET SO FAR
Chairs: Dimitris Mavroudis, Meletios Athanasios Dimopoulos
10:30-11:00 The Go To Action report from New York meeting: Fred Hirsch
11:00-11:30 Twenty Years of Progress in the Treatment of NSCLC:
What Does the Future Hold: Roy S. Herbst